BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25643939)

  • 1. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.
    Poulain S; Boyle EM; Tricot S; Demarquette H; Doye E; Roumier C; Duthilleul P; Preudhomme C; Maurage CA; Morschhauser F
    Br J Haematol; 2015 Jul; 170(2):285-7. PubMed ID: 25643939
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
    Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
    Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
    [No Abstract]   [Full Text] [Related]  

  • 4. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
    Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
    Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
    Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
    Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
    Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
    Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations.
    Ntanasis-Stathopoulos I; Bagratuni T; Gavriatopoulou M; Patseas D; Liacos C; Kanellias N; Fotiou D; Tsiligkeridou E; Andreatou A; Mavrianou-Koutsoukou N; Migkou M; Eleutherakis-Papaiakovou E; Roussou M; Terpos E; Kastritis E; Dimopoulos MA
    Am J Hematol; 2020 Jun; 95(6):E148-E150. PubMed ID: 32242972
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma.
    Montesinos-Rongen M; Schäfer E; Siebert R; Deckert M
    Acta Neuropathol; 2012 Dec; 124(6):905-6. PubMed ID: 23138649
    [No Abstract]   [Full Text] [Related]  

  • 17. Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.
    Gurth M; Bernard V; Bernd HW; Schemme J; Thorns C
    Leuk Lymphoma; 2017 Apr; 58(4):979-981. PubMed ID: 27687087
    [No Abstract]   [Full Text] [Related]  

  • 18. [Detection of MYD88 mutation in lymphoma by PCR-high resolution melting curve analysis].
    Xue D; Lin J; Xiao GF
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):71-3. PubMed ID: 23597472
    [No Abstract]   [Full Text] [Related]  

  • 19. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
    Kraan W; van Keimpema M; Horlings HM; Schilder-Tol EJ; Oud ME; Noorduyn LA; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Leukemia; 2014 Mar; 28(3):719-20. PubMed ID: 24253023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.